Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Miami Cancer Institute at Baptist Health

Neither a doctor nor a teaching hospital

Research payments

$1,304,052

147 payments

Through program year 2025, Miami Cancer Institute at Baptist Health is reported as receiving $1,304,052 in research payments, across 147 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $154,994 30
2024 Research $159,054 31
2023 Research $160,787 18
2022 Research $375,611 27
2021 Research $453,606 41

Breakdown

Who paid Research payments · program years 2021–2025
  1. Blue Earth Diagnostics Limited $1,284,344 139 payments
  2. Genentech, Inc. $14,710 1 payment
  3. Aveo Pharmaceuticals, Inc. $4,098 6 payments
  4. Pfizer Inc. $900 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy $315,753 24 payments
  2. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis $176,181 35 payments
  3. An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy (the Protocol). $156,036 3 payments
  4. An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy $136,953 16 payments
  5. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis (CONCORDANT) $127,500 21 payments
  6. Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery $97,597 18 payments
  7. An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy as it is amended time to time and approved by the IRB (the Protocol) $92,075 3 payments
  8. 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (FACILITATE) $86,273 17 payments
  9. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis $59,677 1 payment
  10. Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery $36,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record